<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">farmaec</journal-id><journal-title-group><journal-title xml:lang="en">FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology</journal-title><trans-title-group xml:lang="ru"><trans-title>ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2070-4909</issn><issn pub-type="epub">2070-4933</issn><publisher><publisher-name>IRBIS LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.17749/2070-4909.2019.12.4.310-317</article-id><article-id custom-type="elpub" pub-id-type="custom">farmaec-321</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ПУБЛИКАЦИИ</subject></subj-group></article-categories><title-group><article-title>Crucial areas of the economic analysis of public cancer care</article-title><trans-title-group xml:lang="ru"><trans-title>Основные направления анализа экономических затрат при оказании онкологической помощи населению</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0745-9474</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Андреев</surname><given-names>Д. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Andreev</surname><given-names>D. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Андреев Дмитрий Анатольевич – ведущий научный сотрудник; ученая степень «доктор», присужденная в Erasmus University Medical Center (Erasmus MC), г. Роттердам, Нидерланды; врач-дерматовенеролог, научно-клинический отдел, ГБУ «Научно-исследовательский институт организации здравоохранения и медицинского менеджмента Департамента здравоохранения г. Москвы».</p><p>ул. Шарикоподшипниковская, д. 9, Москва 115088</p></bio><bio xml:lang="en"><p>Dmitri A. Andreev – МD, PhD, Lead Researcher, Dermatologist, Scientific-Clinical Department, Research Institute for Healthcare Organization and Medical Management of the Moscow Healthcare Department.</p><p>9 Sharikopodshipnikovskaya Str., Moscow 115088</p></bio><email xlink:type="simple">begaafd@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8462-2813</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Полякова</surname><given-names>К. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Polyakova</surname><given-names>K. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Полякова Ксения Игоревна – научный сотрудник, научно-клинический отдел.</p><p>ул. Шарикоподшипниковская, д. 9, Москва 115088</p></bio><bio xml:lang="en"><p>Kseniya I. Polyakova – Researcher, Scientific-Clinical Department.</p><p>9 Sharikopodshipnikovskaya Str., Moscow 115088</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Завьялов</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Zavyalov</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Завьялов Александр Александрович – д.м.н., профессор, врач-онколог, заведующий научно-клиническим отделом.</p><p>ул. Шарикоподшипниковская, д. 9, Москва 115088</p></bio><bio xml:lang="en"><p>Aleksandr A. Zavyalov – МD, PhD, Oncologist, Professor&amp;Head, Scientific – Clinical Department</p><p>9 Sharikopodshipnikovskaya Str., Moscow 115088</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3615-0292</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ермолаева</surname><given-names>Т. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Ermolaeva</surname><given-names>T. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ермолаева Татьяна Николаевна – начальник отдела методологии и эффективности деятельности учреждений здравоохранения по профилю онкология.</p><p>ул. Шарикоподшипниковская, д. 9, Москва 115088</p></bio><bio xml:lang="en"><p>Tatyana N. Ermolaeva – Head of the Department of Methodology and Efficiency of Cancer Care Institutions.</p><p>9 Sharikopodshipnikovskaya Str., Moscow 115088</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9840-3267</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Фисун</surname><given-names>А. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Fisun</surname><given-names>A. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Фисун Анна Геннадьевна – научный сотрудник, научно-клинический отдел.</p><p>ул. Шарикоподшипниковская, д. 9, Москва 115088</p></bio><bio xml:lang="en"><p>Anna G. Fisun – Researcher, Scientific-Clinical Department.</p><p>9 Sharikopodshipnikovskaya Str., Moscow 115088</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ермолаева</surname><given-names>А. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Ermolaeva</surname><given-names>A. D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ермолаева Алина Дмитриевна – научный сотрудник, научно-клинический отдел.</p><p>ул. Шарикоподшипниковская, д. 9, Москва 115088</p></bio><bio xml:lang="en"><p>Alina D. Ermolaeva – Researcher, Scientific-Clinical Department.</p><p>9 Sharikopodshipnikovskaya Str., Moscow 115088</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Дубовцева</surname><given-names>В. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Dubovtseva</surname><given-names>V. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Дубовцева Виктория Алексеевна – научный сотрудник, научно-клинический отдел младший научный сотрудник.</p><p>ул. Шарикоподшипниковская, д. 9, Москва 115088</p></bio><bio xml:lang="en"><p>Viktoriya A. Dubovtseva – Researcher, Scientific-Clinical Department.</p><p>9 Sharikopodshipnikovskaya Str., Moscow 115088</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Максимова</surname><given-names>Т. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Maksimova</surname><given-names>T. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Максимова Тамара Евгеньевна – научный сотрудник, научно-клинический отдел.</p><p>ул. Шарикоподшипниковская, д. 9, Москва 115088</p></bio><bio xml:lang="en"><p>Tamara E. Maksimova – Researcher, Scientific-Clinical Department.</p><p>9 Sharikopodshipnikovskaya Str., Moscow 115088</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">Государственное бюджетное учреждение «Научно-исследовательский институт организации здравоохранения и медицинского менеджмента Департамента здравоохранения г. Москвы»<country>Россия</country></aff><aff xml:lang="en">State Budgetary Institution «Research Institute for Healthcare Organization and Medical Management of Moscow Healthcare Department»<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>18</day><month>02</month><year>2020</year></pub-date><volume>12</volume><issue>4</issue><fpage>310</fpage><lpage>317</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Andreev D.A., Polyakova K.I., Zavyalov A.A., Ermolaeva T.N., Fisun A.G., Ermolaeva A.D., Dubovtseva V.A., Maksimova T.E., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Андреев Д.А., Полякова К.И., Завьялов А.А., Ермолаева Т.Н., Фисун А.Г., Ермолаева А.Д., Дубовцева В.А., Максимова Т.Е.</copyright-holder><copyright-holder xml:lang="en">Andreev D.A., Polyakova K.I., Zavyalov A.A., Ermolaeva T.N., Fisun A.G., Ermolaeva A.D., Dubovtseva V.A., Maksimova T.E.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.pharmacoeconomics.ru/jour/article/view/321">https://www.pharmacoeconomics.ru/jour/article/view/321</self-uri><abstract><sec><title>Introduction</title><p>Introduction. The economic aspects of providing cancer care to the public attract increasing attention of scientists, economists, physicians and other healthcare professionals. Currently, the healthcare economics of oncological institutions is defined as part of the national economy that implements cancer care programs and provide a wide range of medical and pharmaceutical services to the public.</p></sec><sec><title>Aim</title><p>Aim. The study was conducted as part of the program for improvement of financial spending in order to facilitate cancer care for Moscow residents. The aim of this study was to identify the crucial areas of the cost analysis and thus improve the public health service.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. We used the methodology of targeted and consistent search of the literature. The data search and analysis was carried out using the US National Medical Library (PubMed database), National Electronic Library (e-LIBRARY, Russia), and other Internet resources. Whenever possible, articles on the most common and socially significant types of cancer (breast, colon, prostate, lung etc.) were selected. In addition, we focused on significant studies conducted either on the national or international level.</p></sec><sec><title>Results and discussion</title><p>Results and discussion. In principle, the structure of total costs is determined by the health policy regarding the cancer care system. Six main areas of oncological care that require careful economic analysis have been identified: those are prevention, oncoscreening, diagnosis, treatment, rehabilitation, and palliative care. In order to implement the economic goals of the healthcare system, the cost of cancer treatment should be discussed. The relevant programs are expected to be based on 1) prevalence and incidence; 2) impact on health; 3) results of the integrative methodological approach to cancer treatment; 4) implementation of comprehensive measures of medical and social assistance; 5) use of financial mechanisms and their impact on economic indicators.</p></sec><sec><title>Conclusion</title><p>Conclusion. The set of measures related to the direct costs as identified in this study include the development, planning and provision of cancer care. These specific features of the direct cost analysis are important for organizing medical care in oncological institutions.</p></sec></abstract><trans-abstract xml:lang="ru"><sec><title>Введение</title><p>Введение. Экономические вопросы обеспечения онкологической помощи населению привлекают все большее внимание со стороны ученых-экономистов, врачей-организаторов здравоохранения, медицинских менеджеров. В настоящее время под экономикой здравоохранения учреждений онкологического профиля понимается прежде всего отраслевая экономика народного хозяйства, реализующая программы по сохранению и укреплению общего здоровья граждан, профилактики онкозаболеваний и их распространения, предоставления широкого ряда медицинских и фармацевтических услуг по заданным направлениям медицинской помощи.</p><p>Цель – идентификация наиболее важных направлений для анализа экономических затрат, влияющих на эффективность оказания медицинских услуг пациентам с онкологическими заболеваниями.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. В работе применена методология целевого и смыслового поиска источников литературы. Поиск и анализ данных проведен с использованием Национальной медицинской библиотеки США (база данных PubMed), интернет-ресурсов, Национальной электронной библиотеки (НЭБ) e-LIBRARY (Россия). Отбирались статьи, посвященные наиболее распространенным и социально значимым видам рака (рак молочной железы, ободочной кишки, предстательной железы, рак легкого и т. д.). Кроме того, во внимание, главным образом, принимались крупные исследования, проведенные на уровне отдельных государств или обобщающие опыт нескольких стран.</p></sec><sec><title>Результаты и обсуждение</title><p>Результаты и обсуждение. Принципы формирования общих затрат продиктованы политикой здравоохранения в отношении системы оказания онкологической помощи. Идентифицировано шесть основных направлений онкологической помощи, на обеспечение которых распределяются финансовые средства, подлежащие тщательному экономическому анализу: профилактика, онкоскрининг, диагностика, лечение, реабилитация, паллиативная помощь. В целях реализации экономических задач системы здравоохранения следует обсуждать перспективные программы, посвященные вопросам затрат на лечение рака. Эти программы формируются на основании таких коррелирующих данных, как: 1) распространенность и заболеваемость; 2) показатели воздействия на здоровье; 3) результаты внедрения интегративного методического подхода к лечению рака; 4) исходы применения всесторонних мер по оказанию медицинской и социальной помощи; 5) результаты внедрения финансовых механизмов и их влияние на экономические показатели.</p></sec><sec><title>Заключение</title><p>Заключение. В современную профессиональную деятельность всех участников медицинской отрасли входит разработка, планирование и обеспечение комплекса мер, связанных, главным образом, с прямыми затратами на идентифицированные в нашей работе направления. Выявление наиболее важных для последующего исследования особенностей прямых затрат на организацию работы основных направлений медицинской помощи в совокупности с ассоциированными показателями эффективности может способствовать совершенствованию деятельности учреждений здравоохранения онкологического профиля.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>экономика</kwd><kwd>затраты</kwd><kwd>онкологическая помощь</kwd><kwd>организация здравоохранения</kwd><kwd>менеджмент</kwd><kwd>медицинские технологии</kwd></kwd-group><kwd-group xml:lang="en"><kwd>economics</kwd><kwd>costs</kwd><kwd>cancer care</kwd><kwd>healthcare organization</kwd><kwd>management</kwd><kwd>health technologies</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Вялков А.И., Кучеренко В.З., Райзберг Б.А. и др. Управление и экономика здравоохранения. 3-е изд., доп. / Под ред. А.И. Вялкова. М. 2013; 664 с.</mixed-citation><mixed-citation xml:lang="en">Vyalkov A.I., Kucherenko V.Z., Raizberg B.A. et al. Management and health economics. 3rd ed., Ext. / Ed. A.I. Vyalkova. Moscow. 2013; 664 s.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Рак: основные цифры и факты. 2019. [Электронный ресурс] URL: https://www.who.int/cancer/about/facts/ru/. Дата обращения: 14.08.2019.</mixed-citation><mixed-citation xml:lang="en">Cancer: Key Figures and Facts. [Electronic resource] URL: https://www.who.int/cancer/about/facts/ru/. Accessed: 14.08.2019.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2017 году (заболеваемость и смертность). М. 2018; 250 с.</mixed-citation><mixed-citation xml:lang="en">Kaprin A.D., Starinskii V.V., Petrovа G.V. Malignant neoplasms in Russia in 2017 (morbidity and mortality). Moscow. 2018; 250 s.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Каприн А.Д., Старинский В.В., Петрова Г.В. Состояние онкологической помощи населению России в 2017 году. М. 2018; 236 с.</mixed-citation><mixed-citation xml:lang="en">Kaprin A.D., Starinskii V.V., Petrovа G.V. The status of cancer care for the population of Russia in 2017. Moscow. 2018; 236 s.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Latest global cancer data: Cancer burden rises to 18.1 million new cases and 9.6 million cancer deaths in 2018. International Agency for Research on Cancer (WHO) 2018.</mixed-citation><mixed-citation xml:lang="en">Latest global cancer data: Cancer burden rises to 18.1 million new cases and 9.6 million cancer deaths in 2018. International Agency for Research on Cancer (WHO) 2018.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Latest world cancer statistics. Global cancer burden rises to 14.1 million new cases in 2012: Marked increase in breast cancers must be addressed. World Health Organization; 2012.</mixed-citation><mixed-citation xml:lang="en">Latest world cancer statistics. Global cancer burden rises to 14.1 million new cases in 2012: Marked increase in breast cancers must be addressed. World Health Organization; 2012.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Bray F., Soerjomataram I. The Changing Global Burden of Cancer: Transitions in Human Development and Implications for Cancer Prevention and Control. In: Gelband H., Jha P., Sankaranarayanan R., Horton S., editors. Cancer: Disease Control Priorities, Third Edition (Volume 3). Washington (DC) 2015.</mixed-citation><mixed-citation xml:lang="en">Bray F., Soerjomataram I. The Changing Global Burden of Cancer: Transitions in Human Development and Implications for Cancer Prevention and Control. In: Gelband H., Jha P., Sankaranarayanan R., Horton S., editors. Cancer: Disease Control Priorities, Third Edition (Volume 3). Washington (DC) 2015.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Thun M.J., DeLancey J.O., Center M.M., Jemal A., Ward E.M. The global burden of cancer: priorities for prevention. Carcinogenesis. 2010; 31 (1): 100-10. https://doi.org/10.1093/carcin/bgp263.</mixed-citation><mixed-citation xml:lang="en">Thun M.J., DeLancey J.O., Center M.M., Jemal A., Ward E.M. The global burden of cancer: priorities for prevention. Carcinogenesis. 2010; 31 (1): 100-10. https://doi.org/10.1093/carcin/bgp263.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Cancer. Key facts. World Health Organization. 2018. [Electronic resource] URL: https://www.who.int/news-room/fact-sheets/detail/cancer. Accessed: 01.09.2019.</mixed-citation><mixed-citation xml:lang="en">Cancer. Key facts. World Health Organization. 2018. [Electronic resource] URL: https://www.who.int/news-room/fact-sheets/detail/cancer. Accessed: 01.09.2019.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Lyman G.H. Economics of cancer care. J Oncol Pract. 2007; 3 (3): 113-4. https://doi.org/10.1200/JOP.0731501.</mixed-citation><mixed-citation xml:lang="en">Lyman G.H. Economics of cancer care. J Oncol Pract. 2007; 3 (3): 113-4. https://doi.org/10.1200/JOP.0731501.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Игнатьева В.И., Деркач Е.В., Омельяновский В.В., Авксентьева М.В. Социально-экономическое бремя злокачественных новообразований в Российской Федерации. Медицинские технологии. Оценка и выбор. 2013; 4 (14): 73-80.</mixed-citation><mixed-citation xml:lang="en">Ignat’eva V.I., Derkach E.V., Omel’yanovskii V.V., Avksent’eva M.V. The Social and Economic Burden of Cancer in the Russian Federation. Meditsinskie tekhnologii. Otsenka i vybor (in Russ.). 2013; 4 (14): 73-80.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Jönsson B. Cost of Cancer: Healthcare Expenditures and Economic Impact. Regulatory and Economic Aspects in Oncology. Springer, Cham, 2019; 7-23.</mixed-citation><mixed-citation xml:lang="en">Jönsson B. Cost of Cancer: Healthcare Expenditures and Economic Impact. Regulatory and Economic Aspects in Oncology. Springer, Cham, 2019; 7-23.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Greenberg D., Earle C., Fang C.H., Eldar-Lissai A., Neumann P.J. When is cancer care cost-effective? A systematic overview of costutility analyses in oncology. J Natl Cancer Inst. 2010; 102 (2): 82-8. https://doi.org/10.1093/jnci/djp472.</mixed-citation><mixed-citation xml:lang="en">Greenberg D., Earle C., Fang C.H., Eldar-Lissai A., Neumann P.J. When is cancer care cost-effective? A systematic overview of cost-utility analyses in oncology. J Natl Cancer Inst. 2010; 102 (2): 82-8. https://doi.org/10.1093/jnci/djp472.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Авксентьева М.В., Горкавенко Ф.В., Никитина А.В., Савилова А.Г., Герасимова К.В., Мусина Н.З., Омельяновский В.В. Оценка социально-экономического бремени рака легкого в Российской Федерации. Медицинские технологии. Оценка и выбор. 2018. № 4 (34). С. 63-75.</mixed-citation><mixed-citation xml:lang="en">Avksentyeva M.V., Gorkavenko F.V., Nikitina F.V., Savilova A.G., Gerasimova K.V., Musina N.Z., Omelyanovskii V.V. Estimation of Socioeconomic Burden of Lung Cancer in the Russian Federation. Meditsinskie tekhnologii. Otsenka i vybor (in Russ.). 2018. № 4 (34). С. 63-75.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Services USDoHSaH. Fact Book. National Cancer Institute. 2001. [Electronic resource] URL: https://www.cancer.gov/about-nci/budget/fact-book/archive/2001-fact-book.pdf. Accessed: 01.09.2019.</mixed-citation><mixed-citation xml:lang="en">Services USDoHSaH. Fact Book. National Cancer Institute. 2001. [Electronic resource] URL: https://www.cancer.gov/about-nci/budget/fact-book/archive/2001-fact-book.pdf. Accessed: 01.09.2019.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Johnson E.F., Dominici M., Griswold SLZ. Disease cases and their medical costs attributable to smoking: an analysis of the national medical expenditure survey. J Econom. 2003; 112 (1): 135-51.</mixed-citation><mixed-citation xml:lang="en">Johnson E.F., Dominici M., Griswold SLZ. Disease cases and their medical costs attributable to smoking: an analysis of the national medical expenditure survey. J Econom. 2003; 112 (1): 135-51.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Bosanquet N., Karol S. The economics of cancer care: Cambridge University Press; 2006.</mixed-citation><mixed-citation xml:lang="en">Bosanquet N., Karol S. The economics of cancer care: Cambridge University Press; 2006.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Goldie S.J., Daniels N. Model-based analyses to compare health and economic outcomes of cancer control: inclusion of disparities. J Natl Cancer Inst. 2011; 103 (18): 1373-86. https://doi.org/10.1093/jnci/djr303.</mixed-citation><mixed-citation xml:lang="en">Goldie S.J., Daniels N. Model-based analyses to compare health and economic outcomes of cancer control: inclusion of disparities. J Natl Cancer Inst. 2011; 103 (18): 1373-86. https://doi.org/10.1093/jnci/djr303.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Wong W.B., Wu N., Yang E., Davies J., Chae Y.K. Real-World Clinical and Economic Outcomes and the Role of Bevacizumab in Patients With Non-Small-Cell Lung Cancer With Liver Metastases. J Oncol Pract. 2019; 15 (10): e878-e87. https://doi.org/10.1200/JOP.19.00166.</mixed-citation><mixed-citation xml:lang="en">Wong W.B., Wu N., Yang E., Davies J., Chae Y.K. Real-World Clinical and Economic Outcomes and the Role of Bevacizumab in Patients With Non-Small-Cell Lung Cancer With Liver Metastases. J Oncol Pract. 2019; 15 (10): e878-e87. https://doi.org/10.1200/JOP.19.00166.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Lee J.A., Kim S.Y., Park K., Park E.C., Park J.H. Analysis of Hospital Volume and Factors Influencing Economic Outcomes in Cancer Surgery: Results from a Population-based Study in Korea. Osong Public Health Res Perspect. 2017; 8 (1): 34-46. https://doi.org/10.24171/j.phrp.2017.8.1.05.</mixed-citation><mixed-citation xml:lang="en">Lee J.A., Kim S.Y., Park K., Park E.C., Park J.H. Analysis of Hospital Volume and Factors Influencing Economic Outcomes in Cancer Surgery: Results from a Population-based Study in Korea. Osong Pub lic Health Res Perspect. 2017; 8 (1): 34-46. https://doi.org/10.24171/j.phrp.2017.8.1.05.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Fryback D.G., Craig B.M. Measuring economic outcomes of cancer. J Natl Cancer Inst Monogr. 2004; 33: 134-41.</mixed-citation><mixed-citation xml:lang="en">Fryback D.G., Craig B.M. Measuring economic outcomes of cancer. J Natl Cancer Inst Monogr. 2004; 33: 134-41.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Homan S.G., Yun S., Bouras A., Schmaltz C., Gwanfogbe P., Lucht J. Breast Cancer Population Screening Program Results in Early Detection and Reduced Treatment and Health Care Costs for Medicaid. J Public Health Manag Pract. 2019. https://doi.org/10.1097/PHH.0000000000001041.</mixed-citation><mixed-citation xml:lang="en">Homan S.G., Yun S., Bouras A., Schmaltz C., Gwanfogbe P., Lucht J. Breast Cancer Population Screening Program Results in Early Detection and Reduced Treatment and Health Care Costs for Medicaid. J Public Health Manag Pract. 2019. https://doi.org/10.1097/PHH.0000000000001041.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Kim E.Y., Shim Y.S., Kim Y.S., Lee S.P., Ko K.D., Choi W.J. Adherence to general medical checkup and cancer screening guidelines according to self-reported smoking status: Korea National Health and Nutrition Examination Survey (KNHANES) 2010-2012. PLoS One. 2019; 14 (10): e0224224. https://doi.org/10.1371/journal.pone.0224224.</mixed-citation><mixed-citation xml:lang="en">Kim E.Y., Shim Y.S., Kim Y.S., Lee S.P., Ko K.D., Choi W.J. Adherence to general medical checkup and cancer screening guidelines according to self-reported smoking status: Korea National Health and Nutrition Examination Survey (KNHANES) 2010-2012. PLoS One. 2019; 14 (10): e0224224. https://doi.org/10.1371/journal.pone.0224224.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Stewart B.W., Kleihues P. World cancer report: IARCPress; 2003.</mixed-citation><mixed-citation xml:lang="en">Stewart B.W., Kleihues P. World cancer report: IARCPress; 2003.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Giovagnoli M.R., Bonifacino A., Neglia C., Benvenuto M., Sambati FV., Giolli L., et al. Diagnostic and therapeutic path of breast cancer: effectiveness, appropriateness, and costs – results from the DOCMa study. Clin Interv Aging. 2015; 10: 741-9. https://doi.org/10.2147/CIA.S75486.</mixed-citation><mixed-citation xml:lang="en">Giovagnoli M.R., Bonifacino A., Neglia C., Benvenuto M., Sambati FV., Giolli L., et al. Diagnostic and therapeutic path of breast cancer: effectiveness, appropriateness, and costs – results from the DOCMa study. Clin Interv Aging. 2015; 10: 741-9. https://doi.org/10.2147/CIA.S75486.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Bosanquet N., Salisbury C. Providing a Palliative Care Service Towards an Evidence Base. OUP, UK. 1999.</mixed-citation><mixed-citation xml:lang="en">Bosanquet N., Salisbury C. Providing a Palliative Care Service Towards an Evidence Base. OUP, UK. 1999.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Lafuma A., Cotte F.E., Le Tourneau C., Emery C., Gaudin A.F., Torreton E., et al. Economic burden of chemotherapy-treated recurrent and/or metastatic squamous cell carcinoma of the head and neck in France: real-world data from the permanent sample of national health insurance beneficiaries. J Med Econ. 2019; 22 (7): 698-705. https://doi.org/10.1080/13696998.2019.1594837.</mixed-citation><mixed-citation xml:lang="en">Lafuma A., Cotte F.E., Le Tourneau C., Emery C., Gaudin A.F., Torreton E., et al. Economic burden of chemotherapy-treated recurrent and/or metastatic squamous cell carcinoma of the head and neck in France: real-world data from the permanent sample of national health insurance beneficiaries. J Med Econ. 2019; 22 (7): 698-705. https://doi.org/10.1080/13696998.2019.1594837.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Rashid N., Koh H.A., Baca H.C., Lin K.J., Malecha S.E., Masaquel A. Economic burden related to chemotherapy-related adverse events in patients with metastatic breast cancer in an integrated health care system. Breast Cancer (Dove Med Press). 2016; 8: 173-81. https://doi.org/10.2147/BCTT.S105618.</mixed-citation><mixed-citation xml:lang="en">Rashid N., Koh H.A., Baca H.C., Lin K.J., Malecha S.E., Masaquel A. Economic burden related to chemotherapy-related adverse events in patients with metastatic breast cancer in an integrated health care system. Breast Cancer (Dove Med Press). 2016; 8: 173-81. https://doi.org/10.2147/BCTT.S105618.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Peng Y., Ma F., Tan C., Wan X., Yi L., Peng L., et al. Model-Based Economic Evaluation of Ceritinib and Platinum-Based Chemotherapy as First-Line Treatments for Advanced Non-Small Cell Lung Cancer in China. Adv Ther. 2019; https://doi.org/10.1007/s12325-019-01103-4.</mixed-citation><mixed-citation xml:lang="en">Peng Y., Ma F., Tan C., Wan X., Yi L., Peng L., et al. Model-Based Economic Evaluation of Ceritinib and Platinum-Based Chemotherapy as First-Line Treatments for Advanced Non-Small Cell Lung Cancer in China. Adv Ther. 2019; https://doi.org/10.1007/s12325-019-01103-4.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Зеленова О.В., Болотина Л.В., Русаков И.Г., Ивахненко О.И., Крысанов И.С. Экономическое сравнение различных методов лечения генерализованного рака почки. Прямые медицинские затраты в онкологическом стационаре. Креативная хирургия и онкология. 2011; 4: 73-8.</mixed-citation><mixed-citation xml:lang="en">Zelenova O.V., Bolotina L.V., Rusakov I.G., Ivakhnenko O.I., Krysanov I.S. An economic comparison of different treatments for generalized kidney cancer. Direct medical expenses in an oncology hospital. Kreativnaya khirurgiya i onkologiya (in Russ). 2011; 4: 73-8.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Heitland W., Schadlich P.K., Chen X., Remy V., Moro L. Annual cost of hospitalization, inpatient rehabilitation and sick leave of anal cancer in Germany. J Med Econ. 2013; 16 (3): 364-71. https://doi.org/10.3111/13696998.2012.759582.</mixed-citation><mixed-citation xml:lang="en">Heitland W., Schadlich P.K., Chen X., Remy V., Moro L. Annual cost of hospitalization, inpatient rehabilitation and sick leave of anal cancer in Germany. J Med Econ. 2013; 16 (3): 364-71. https://doi.org/10.3111/13696998.2012.759582.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Round J., Leurent B., Jones L. A cost-utility analysis of a rehabilitation service for people living with and beyond cancer. BMC Health Serv Res. 2014; 14: 558. https://doi.org/10.1186/s12913-0140558-5.</mixed-citation><mixed-citation xml:lang="en">Round J., Leurent B., Jones L. A cost-utility analysis of a rehabilitation service for people living with and beyond cancer. BMC Health Serv Res. 2014; 14: 558. https://doi.org/10.1186/s12913-014-0558-5.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Mewes J.C., Steuten L.M., Ijzerman M.J., van Harten WH. Effectiveness of multidimensional cancer survivor rehabilitation and cost-effectiveness of cancer rehabilitation in general: a systematic review. Oncologist. 2012; 17 (12): 1581-93. https://doi.org/10.1634/theoncologist.2012-0151.</mixed-citation><mixed-citation xml:lang="en">Mewes J.C., Steuten L.M., Ijzerman M.J., van Harten WH. Effectiveness of multidimensional cancer survivor rehabilitation and cost-effectiveness of cancer rehabilitation in general: a systematic review. Oncologist. 2012; 17 (12): 1581-93. https://doi.org/10.1634/theoncologist.2012-0151.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Gordon L.G., Scuffham P., Battistutta D., Graves N., Tweeddale M., Newman B. A cost-effectiveness analysis of two rehabilitation support services for women with breast cancer. Breast Cancer Res Treat. 2005; 94 (2): 123-33. https://doi.org/10.1007/s10549-0055828-9.</mixed-citation><mixed-citation xml:lang="en">Gordon L.G., Scuffham P., Battistutta D., Graves N., Tweeddale M., Newman B. A cost-effectiveness analysis of two rehabilitation support services for women with breast cancer. Breast Cancer Res Treat. 2005; 94 (2): 123-33. https://doi.org/10.1007/s10549-005-5828-9.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Enguidanos S.M., Cherin D., Brumley R. Home-based palliative care study: site of death, and costs of medical care for patients with congestive heart failure, chronic obstructive pulmonary disease, and cancer. J Soc Work End Life Palliat Care. 2005; 1 (3): 37-56. https://doi.org/10.1300/J457v01n03_04.</mixed-citation><mixed-citation xml:lang="en">Enguidanos S.M., Cherin D., Brumley R. Home-based palliative care study: site of death, and costs of medical care for patients with congestive heart failure, chronic obstructive pulmonary disease, and cancer. J Soc Work End Life Palliat Care. 2005; 1 (3): 37-56. https://doi.org/10.1300/J457v01n03_04.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Guest J.F., Ruiz F.J., Greener M.J., Trotman I.F. Palliative care treatment patterns and associated costs of healthcare resource use for specific advanced cancer patients in the UK. Eur J Cancer Care (Engl). 2006; 15 (1): 65-73. https://doi.org/10.1111/j.1365-2354.2005.00623.x.</mixed-citation><mixed-citation xml:lang="en">Guest J.F., Ruiz F.J., Greener M.J., Trotman I.F. Palliative care treatment patterns and associated costs of healthcare resource use for specific advanced cancer patients in the UK. Eur J Cancer Care (Engl). 2006; 15 (1): 65-73. https://doi.org/10.1111/j.1365-2354.2005.00623.x.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Witteveen P.O., van Groenestijn M.A., Blijham G.H., Schrijvers A.J. Use of resources and costs of palliative care with parenteral fluids and analgesics in the home setting for patients with end-stage cancer. Ann Oncol. 1999; 10 (2): 161-5. https://doi.org/10.1023/a:1008364401890.</mixed-citation><mixed-citation xml:lang="en">Witteveen P.O., van Groenestijn M.A., Blijham G.H., Schrijvers A.J. Use of resources and costs of palliative care with parenteral fluids and analgesics in the home setting for patients with end-stage cancer. Ann Oncol. 1999; 10 (2): 161-5. https://doi.org/10.1023/a:1008364401890.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Bates M.J., Namisango E., Tomeny E., Muula A., Squire S.B., Niessen L. Palliative care within universal health coverage: the Malawi Patient-and-Carer Cancer Cost Survey. BMJ Support Palliat Care. 2019; https://doi.org/10.1136/bmjspcare-2019-001945.</mixed-citation><mixed-citation xml:lang="en">Bates M.J., Namisango E., Tomeny E., Muula A., Squire S.B., Niessen L. Palliative care within universal health coverage: the Malawi Patient-and-Carer Cancer Cost Survey. BMJ Support Palliat Care. 2019; https://doi.org/10.1136/bmjspcare-2019-001945.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Saygili M., Celik Y. An evaluation of the cost-effectiveness of the different palliative care models available to cancer patients in Turkey. Eur J Cancer Care (Engl). 2019; 28 (5): e13110. https://doi.org/10.1111/ecc.13110.</mixed-citation><mixed-citation xml:lang="en">Saygili M., Celik Y. An evaluation of the cost-effectiveness of the different palliative care models available to cancer patients in Turkey. Eur J Cancer Care (Engl). 2019; 28 (5): e13110. https://doi.org/10.1111/ecc.13110.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Rozman L.M., Campolina A.G., Lopez R.M., Chiba T., De Soarez P.C. Palliative cancer care: costs in a Brazilian quaternary hospital. BMJ Support Palliat Care. 2019. https://doi.org/10.1136/bmjspcare-2019-001809.</mixed-citation><mixed-citation xml:lang="en">Rozman L.M., Campolina A.G., Lopez R.M., Chiba T., De Soarez P.C. Palliative cancer care: costs in a Brazilian quaternary hospital. BMJ Support Palliat Care. 2019. https://doi.org/10.1136/bmjspcare-2019-001809.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Андреев Д.А., Башлакова Е.Е., Хачанова Н.В., Давыдовская М.В. Регистры больных муковисцидозом: отечественный и зарубежный опыт. Педиатрическая фармакология. 2017; 14 (2): 115-26.</mixed-citation><mixed-citation xml:lang="en">Andreev D.A., Bashlakova E.E., Khachanova N.V., Davydovskaia M.V. Cystic Fibrosis Patient Registries: Domestic and Foreign Experience. Pediatric pharmacology (In Russ.). 2017; 14 (2): 115-126/ https://doi.org/10.15690/pf.v14i2.1726.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Башлакова Е.Е., Андреев Д.А., Хачанова Н.В., Давыдовская М.В. Регистры. Виды регистров. Регистры больных гемофилией (обзор). Врач и информационные технологии. 2018; 1: 33-42.</mixed-citation><mixed-citation xml:lang="en">Bashlakova E.E., Andreev D.A., Khachanova N.V., Davydovskaya M.V. Registry. Registries. Types of registries. Registries of Hemophilia (review). Vrach i informatsionnye tekhnologii (in Russ). 2018; 1: 33-42.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Андреев Д.А., Хачанова Н.В., Кокушкин К.А., Давыдовская М.В. Стандартизованные регистры пациентов с рассеянным склерозом – важный инструмент при переходе на ценностно-ориентированное здравоохранение. Проблемы стандартизации в здравоохранении. 2018; 3-4: 35-45.</mixed-citation><mixed-citation xml:lang="en">Andreev D.A., Khachanova N.V., Kokushkin K.A., Davydovskaya M.V. Multiple sclerosis registries as a vital element in the transition to the value-based healthcare. Problemy standartizatsii v zdravookhranenii (in Russ). 2018; 3-4: 35-45.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
